Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis
- 1 October 2017
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (10) , 1751-1754
Abstract
Objective Although anticitrullinated protein antibody (ACPA)-positive and ACPA-negative rheumatoid arthritis (RA) have different aetiopathology, the clinical presentation at the time of diagnosis is similar. This study evaluated whether there are phenotypic differences in the symptomatic pre-RA phase. Methods Patients with arthralgia included in the Leiden clinically suspect arthralgia cohort who developed arthritis during follow-up were studied (n=67). Symptoms at symptom onset, symptoms and signs at presentation with arthralgia and time to arthritis development were compared between ACPA-positive and ACPA-negative patients. Results In ACPA-negative patients (n=37), the location of initial symptoms less often included the lower extremities (22% vs 50%, p=0.014). At presentation with arthralgia, ACPA-positive patients had a longer symptom duration (median 22 vs 14 weeks, p=0.005), less tender joints (mean 5 vs 9, p=0.007) and less difficulty making a fist (11% vs 43%, p=0.004). However, after presentation with arthralgia, ACPA-positive patients developed arthritis more quickly (median 6 vs 18 weeks, p=0.015). A partial least squares regression analysis showed clustering of ACPA-positive and ACPA-negative patients based on the above-mentioned clinical variables. Conclusion This study is the first showing that ACPA-positive and ACPA-negative patients have clinical differences in the symptomatic phase preceding clinical arthritis. This contributes to the notion that ACPA-positive and ACPA-negative RA develop differently.Keywords
This publication has 16 references indexed in Scilit:
- Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRIAnnals of the Rheumatic Diseases, 2015
- The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA: Table 1Rheumatology, 2014
- Subclinical inflammation on MRI of hand and foot of anticitrullinated peptide antibody–negative arthralgia patients at risk for rheumatoid arthritisArthritis Research & Therapy, 2014
- Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patientsAnnals of the Rheumatic Diseases, 2012
- A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritisAnnals of the Rheumatic Diseases, 2011
- A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullinationArthritis & Rheumatism, 2005
- Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progressionAnnals of the Rheumatic Diseases, 2005
- Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritisArthritis Research & Therapy, 2005
- Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donorsArthritis & Rheumatism, 2004
- Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritisArthritis & Rheumatism, 2003